Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

ASH 2024 Insights: De-Escalated PTCy & Ruxolitinib for GVHD Prophyla…

2024 ASH Annual Meeting Insights Hub

S. Abedin

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

GVHD: Importance of Early Detection and Management

Ernst Holler

Identifying Steroid-Refractory or Steroid-Dependent cGVHD and the Ro…

Elisabetta Xue

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

Current and Future Therapeutic Approaches to cGVHD

Kirk Schultz

Correlation of PROs and Organ Response in Belumosudil-Treated cGVHD:…

Levanto Schachter

Understanding New Strategies to Prevent and Manage Chronic GVHD

2024 ASCO® Annual Meeting Insights Hub

B. Hamilton

CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD

Najla El-Jurdi

ASH 2024 Insights: Real-World Ruxolitinib and Corticosteroid Treatme…

2024 ASH Annual Meeting Insights Hub

C. Lee

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

The Role of CSF1R in Modulating Inflammation and Fibrosis

Fred Hutchinson Cancer Center

R. Adams

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon

Maintaining QoL in Chronic GvHD

Nandita Khera

HSCT & Cell Therapy 101: Overview of Types, Processes, Supportive Ca…

GRACE

M. Salman Faisal

Approaches to Preventing and Treating GVHD in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

N. Hossain